Logo

Nanogen Subsidiary SynX Signs on Five European Distributors

Mar 08, 2005

NEW YORK, March 8 (GenomeWeb News) - Nanogen's subsidiary SynX has signed on five European distributors for its point-of-care diagnostics products, Nanogen said today.

 

The new distributors, which Nanogen did not name, expand SynX's coverage to 28 European countries. They will distribute and market SynX's point-of-care tests and research products for congestive heart failure and myocardial infarction.

 

SynX said its CHF diagnostic test is expected to lauch this year.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.